title: [Effect of tongguan capsule on coagulant and fibrinolysis system in patients with coronary heart disease after percutaneous coronary intervention].
abstract: OBJECTIVE
  To explore the effect and mechanism of Tongguan capsule (TGC) on coagulant and fibrinolysis system in patients with coronary heart disease (CHD) after percutaneous coronary intervention (PCI).
  
  
  METHODS
  Adopting the prospective, randomized controlled method to observe the coagulant-fibrinolysis related indexes, including tissue plasminogen activator (t-PA), plasminogen activator inhibitor 1 (PAI-1), von Willebrand factor (vWF), antithrombin II (AT-III) and fibrinogen (FIB), in CHD patients after PCI, there were 26 patients in the treated group treated by TGC with Western medicine and 26 in the control group treated by Western medicine alone.
  
  
  RESULTS
  After treatment, all the indexes were improved in both groups (P < 0.05). As comparison between the two groups, AT-III and t-PA were higher in the treated group than those in the control group; PAI-1 levels showed insignificant difference at 1 month after treatment, but at 3 months after treatment, it was significantly lower in the treated group (P < 0.05); vWF showed no significant difference either at 1 or at 3 months after treatment; and FIB was lower in the treated group both at 1 and 3 months after treatment (P < 0.01).
  
  
  CONCLUSIONS
  TGC could improve the hypercoagulant status and adjust the balance between coagulant-fibrinolysis system of CHD patients after PCI by increasing AT-III and t-PA levels, and lowering FIB and PAI-1 levels in the body.
authors.affiliation: Guangdong Provincial Hospital of TCM, Guangzhou 510120. xixi96@hotmail.com
authors.forename: Xiang-Wei
authors.initials: XW
authors.lastname: Zhang
authors.forename: Min-Zhou
authors.initials: MZ
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary; D000990:Antithrombin III / Q000032:analysis; D002214:Capsules; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy* / Q000628:therapy; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D005342:Fibrinolysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D011446:Prospective Studies; D015607:Stents; D010959:Tissue Plasminogen Activator / Q000097:blood; D014841:von Willebrand Factor / Q000032:analysis
chemical_list: D002214:Capsules; D004365:Drugs, Chinese Herbal; D017395:Plasminogen Activator Inhibitor 1; D014841:von Willebrand Factor; D000990:Antithrombin III; D010959:Tissue Plasminogen Activator